{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:16:48Z","timestamp":1781090208474,"version":"3.54.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100017699","name":"Galecto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["VR150122"],"award-info":[{"award-number":["VR150122"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007745","name":"Massachusetts Lions Eye Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007745","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajp.amjpathol.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ajpath.2023.11.018","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T16:26:05Z","timestamp":1703780765000},"page":"447-458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Anti-Angiogenic and Anti-Scarring Dual Effect of Galectin-3 Inhibition in Mouse Models of Corneal Wound Healing"],"prefix":"10.1016","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0235-9053","authenticated-orcid":false,"given":"Zhiyi","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulraouf","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7771-0850","authenticated-orcid":false,"given":"Albert","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7789-8782","authenticated-orcid":false,"given":"Fredrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0821-9686","authenticated-orcid":false,"given":"Noorjahan","family":"Panjwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2023.11.018_bib1","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.eye.6701973","article-title":"The impact of Vision 2020 on global blindness","volume":"19","author":"Foster","year":"2005","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ajpath.2023.11.018_bib2","first-page":"214","article-title":"Corneal blindness: a global perspective","volume":"79","author":"Whitcher","year":"2001","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.ajpath.2023.11.018_bib3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00003226-200304000-00021","article-title":"Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology","volume":"22","author":"Cursiefen","year":"2003","journal-title":"Cornea"},{"key":"10.1016\/j.ajpath.2023.11.018_bib4","first-page":"2485","article-title":"Loss and restoration of immune privilege in eyes with corneal neovascularization","volume":"37","author":"Dana","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajpath.2023.11.018_bib5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10792-007-9099-9","article-title":"Graft failure IV. Immunologic mechanisms of corneal transplant rejection","volume":"28","author":"Chong","year":"2008","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.ajpath.2023.11.018_bib6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/ACI.0b013e32833dfa11","article-title":"High-risk corneal allografts and why they lose their immune privilege","volume":"10","author":"Niederkorn","year":"2010","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.ajpath.2023.11.018_bib7","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0041-1345(99)00010-X","article-title":"Anterior chamber-associated immune deviation, ocular immune privilege, and orthotopic corneal allografts","volume":"31","author":"Streilein","year":"1999","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ajpath.2023.11.018_bib8","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.4103\/0976-500X.120947","article-title":"Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases","volume":"4","author":"Ventrice","year":"2013","journal-title":"J Pharmacol Pharmacother"},{"key":"10.1016\/j.ajpath.2023.11.018_bib9","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.survophthal.2012.01.007","article-title":"Corneal neovascularization: an anti-VEGF therapy review","volume":"57","author":"Chang","year":"2012","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ajpath.2023.11.018_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100906","article-title":"Incomplete response to anti-VEGF therapy in neovascular AMD: exploring disease mechanisms and therapeutic opportunities","volume":"82","author":"Mettu","year":"2021","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ajpath.2023.11.018_bib11","first-page":"1857","article-title":"Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review","volume":"10","author":"Yang","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ajpath.2023.11.018_bib12","doi-asserted-by":"crossref","first-page":"29913","DOI":"10.1074\/jbc.M111.226423","article-title":"Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells","volume":"286","author":"Markowska","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2023.11.018_bib13","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1084\/jem.20090121","article-title":"Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response","volume":"207","author":"Markowska","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.ajpath.2023.11.018_bib14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/ATVBAHA.112.300569","article-title":"Galectin-3 mediates aldosterone-induced vascular fibrosis","volume":"33","author":"Calvier","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ajpath.2023.11.018_bib15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2353\/ajpath.2008.070726","article-title":"Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis","volume":"172","author":"Henderson","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajpath.2023.11.018_bib16","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1073\/pnas.0511167103","article-title":"Galectin-3 regulates myofibroblast activation and hepatic fibrosis","volume":"103","author":"Henderson","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2023.11.018_bib17","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1164\/rccm.201106-0965OC","article-title":"Regulation of transforming growth factor-\u03b21-driven lung fibrosis by galectin-3","volume":"185","author":"Mackinnon","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ajpath.2023.11.018_bib18","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.4049\/jimmunol.180.4.2650","article-title":"Regulation of alternative macrophage activation by galectin-3","volume":"180","author":"MacKinnon","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.ajpath.2023.11.018_bib19","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1517\/13543776.2014.947961","article-title":"Galectin-3 inhibitors: a patent review (2008-present)","volume":"24","author":"Blanchard","year":"2014","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.ajpath.2023.11.018_bib20","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.208884","article-title":"Galectins at a glance","volume":"131","author":"Johannes","year":"2018","journal-title":"J Cell Sci"},{"key":"10.1016\/j.ajpath.2023.11.018_bib21","doi-asserted-by":"crossref","first-page":"8116","DOI":"10.3390\/ijms24098116","article-title":"Development of galectin-3 targeting drugs for therapeutic applications in various diseases","volume":"24","author":"Ahmed","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajpath.2023.11.018_bib22","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1039\/D2CS00954D","article-title":"Glycomimetics for the inhibition and modulation of lectins","volume":"52","author":"Leusmann","year":"2023","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.ajpath.2023.11.018_bib23","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/13543776.2021.1903430","article-title":"An updated patent review of galectin-1 and galectin-3 inhibitors and their potential therapeutic applications (2016-present)","volume":"31","author":"Sethi","year":"2021","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.ajpath.2023.11.018_bib24","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/cbic.201600285","article-title":"Galectin-3-binding glycomimetics that strongly reduce bleomycin-induced lung fibrosis and modulate intracellular glycan recognition","volume":"17","author":"Delaine","year":"2016","journal-title":"Chembiochem"},{"key":"10.1016\/j.ajpath.2023.11.018_bib25","doi-asserted-by":"crossref","first-page":"11084","DOI":"10.1021\/acs.jmedchem.2c00517","article-title":"Identification of monosaccharide derivatives as potent, selective, and orally bioavailable inhibitors of human and mouse galectin-3","volume":"65","author":"Liu","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.ajpath.2023.11.018_bib26","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1021\/acs.jmedchem.7b01626","article-title":"Systematic tuning of fluoro-galectin-3 interactions provides thiodigalactoside derivatives with single-digit nM affinity and high selectivity","volume":"61","author":"Peterson","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.ajpath.2023.11.018_bib27","doi-asserted-by":"crossref","first-page":"12626","DOI":"10.1021\/acs.jmedchem.2c00660","article-title":"Discovery and optimization of the first highly effective and orally available galectin-3 inhibitors for treatment of fibrotic disease","volume":"65","author":"Zetterberg","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.ajpath.2023.11.018_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1167\/iovs.16-20009","article-title":"Galectin-3 inhibition by a small-molecule inhibitor reduces both pathological corneal neovascularization and fibrosis","volume":"58","author":"Chen","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajpath.2023.11.018_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.108272","article-title":"Corneal myofibroblasts and fibrosis","volume":"201","author":"Wilson","year":"2020","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ajpath.2023.11.018_bib30","doi-asserted-by":"crossref","first-page":"42299","DOI":"10.1074\/jbc.M200981200","article-title":"Galectins-3 and -7, but not galectin-1, play a role in re-epithelialization of wounds","volume":"277","author":"Cao","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2023.11.018_bib31","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/imr.12289","article-title":"Bacterial recognition pathways that lead to inflammasome activation","volume":"265","author":"Storek","year":"2015","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ajpath.2023.11.018_bib32","first-page":"609","article-title":"Targeting toll-like receptor signaling as a novel approach to prevent ocular infectious diseases","volume":"138","author":"Pandey","year":"2013","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.ajpath.2023.11.018_bib33","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cell.2016.03.046","article-title":"Inflammasome complexes: emerging mechanisms and effector functions","volume":"165","author":"Rathinam","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ajpath.2023.11.018_bib34","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1074\/jbc.M113.523167","article-title":"CD14 mediates Toll-like receptor 4 (TLR4) endocytosis and spleen tyrosine kinase (Syk) and interferon regulatory transcription factor 3 (IRF3) activation in epithelial cells and impairs neutrophil infiltration and Pseudomonas aeruginosa killing in\u00a0vivo","volume":"289","author":"Roy","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2023.11.018_bib35","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1100\/2011\/212680","article-title":"Role of the inflammasome, IL-1[beta], and IL-18 in bacterial infections","volume":"11","author":"Sahoo","year":"2011","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.ajpath.2023.11.018_bib36","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41581-018-0026-2","article-title":"IL-1[beta] switches on kidney fibrosis","volume":"14","author":"Otto","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ajpath.2023.11.018_bib37","doi-asserted-by":"crossref","first-page":"e1847","DOI":"10.1038\/cddis.2015.206","article-title":"Chop deficiency prevents UUO-induced renal fibrosis by attenuating fibrotic signals originated from Hmgb1\/TLR4\/NF[kappa]B\/IL-1[beta] signaling","volume":"6","author":"Zhang","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ajpath.2023.11.018_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10791","article-title":"IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis","volume":"7","author":"Iannitti","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2023.11.018_bib39","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1146\/annurev-immunol-031210-101405","article-title":"The inflammasome NLRs in immunity, inflammation, and associated diseases","volume":"29","author":"Davis","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ajpath.2023.11.018_bib40","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","article-title":"Immunological and inflammatory functions of the interleukin-1 family","volume":"27","author":"Dinarello","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ajpath.2023.11.018_bib41","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00441-016-2387-9","article-title":"The role of IL-1[beta] in Pseudomonas aeruginosa in lung infection","volume":"364","author":"Wonnenberg","year":"2016","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.ajpath.2023.11.018_bib42","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2023.11.018_bib43","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1164\/rccm.201905-1013OC","article-title":"Specific inhibition of the NLRP3 inflammasome as an antiinflammatory strategy in cystic fibrosis","volume":"200","author":"McElvaney","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ajpath.2023.11.018_bib44","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/cvr\/cvy252","article-title":"Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension","volume":"115","author":"Krishnan","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ajpath.2023.11.018_bib45","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.3390\/ijms21145097","article-title":"Galectin-3 in inflammasome activation and primary biliary cholangitis development","volume":"21","author":"Arsenijevic","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajpath.2023.11.018_bib46","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ajpath.2017.12.014","article-title":"Galectin-3 enhances avian H5N1 influenza A virus-induced pulmonary inflammation by promoting NLRP3 inflammasome activation","volume":"188","author":"Chen","year":"2018","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajpath.2023.11.018_bib47","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/ecco-jcc\/jjw013","article-title":"Galectin-3 plays an important pro-inflammatory role in the induction phase of acute colitis by promoting activation of NLRP3 inflammasome and production of IL-1[beta] in macrophages","volume":"10","author":"Simovic Markovic","year":"2016","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.ajpath.2023.11.018_bib48","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1096\/fj.201600392RR","article-title":"Galectin-3 regulates inflammasome activation in cholestatic liver injury","volume":"30","author":"Tian","year":"2016","journal-title":"FASEB J"},{"key":"10.1016\/j.ajpath.2023.11.018_bib49","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.3390\/ijms23105548","article-title":"Galectin 1--a key player between tissue repair and fibrosis","volume":"23","author":"Hermenean","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajpath.2023.11.018_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/cddiscovery.2017.10","article-title":"Galectin-1 inhibition attenuates profibrotic signaling in hypoxia-induced pulmonary fibrosis","volume":"3","author":"Kathiriya","year":"2017","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.ajpath.2023.11.018_bib51","first-page":"103","article-title":"Galectin-1 gene silencing inhibits the activation and proliferation but induces the apoptosis of hepatic stellate cells from mice with liver fibrosis","volume":"43","author":"Jiang","year":"2019","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.ajpath.2023.11.018_bib52","article-title":"Glycosylation-dependent galectin-1\/neuropilin-1 interactions promote liver fibrosis through activation of TGF-\u03b2- and PDGF-like signals in hepatic stellate cells","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajpath.2023.11.018_bib53","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2023.11.018_bib54","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944023004868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944023004868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T01:42:22Z","timestamp":1740793342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944023004868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0002944023004868"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2023.11.018","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-Angiogenic and Anti-Scarring Dual Effect of Galectin-3 Inhibition in Mouse Models of Corneal Wound Healing","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2023.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}